Document
IPR2024-00107, No. 1091 Exhibit - Declaration of Melissa Weinberg, MD (P.T.A.B. Nov. 2, 2023)
Cite Document
IPR2024-00107, No. 1091 Exhibit - Declaration of Melissa Weinberg, MD (P.T.A.B. Nov. 2, 2023)
+ More Snippets
Document
IPR2024-00107, No. 1066 Exhibit - Knudsen, Liraglutide The Therapeutic Promise from Animal Models, 64suppl (P.T.A.B. Nov. 2, 2023)
Cite Document
IPR2024-00107, No. 1066 Exhibit - Knudsen, Liraglutide The Therapeutic Promise from Animal Models, 64suppl (P.T.A.B. Nov. 2, 2023)
+ More Snippets
Document
IPR2024-00107, No. 1044 Exhibit - Rohatagi, Model Based Development of a PPARγ Agonist, Rivoglitazone, to Aid (P.T.A.B. Nov. 2, 2023)
Cite Document
IPR2024-00107, No. 1044 Exhibit - Rohatagi, Model Based Development of a PPARγ Agonist, Rivoglitazone, to Aid (P.T.A.B. Nov. 2, 2023)
+ More Snippets
Document
IPR2024-00107, No. 1036 Exhibit - Mojsov, Insulinotropin Glucagon like Peptide I 7 37 Co encoded in the Gl (P.T.A.B. Nov. 2, 2023)
Cite Document
IPR2024-00107, No. 1036 Exhibit - Mojsov, Insulinotropin Glucagon like Peptide I 7 37 Co encoded in the Gl (P.T.A.B. Nov. 2, 2023)
+ More Snippets
Document
IPR2024-00107, No. 1094 Exhibit - CV of Craig Dyar, PhD (P.T.A.B. Nov. 2, 2023)
Cite Document
IPR2024-00107, No. 1094 Exhibit - CV of Craig Dyar, PhD (P.T.A.B. Nov. 2, 2023)
+ More Snippets
Document
IPR2024-00107, No. 2028 Exhibit - EX2028 Excerpt of Opening Expert Report of Dr John Bantle Regarding Invalidity of US Patent No 10,335,462, In re Ozempic Semaglutide Patent Litigation, No 22 MD 030
Cite Document
IPR2024-00107, No. 2028 Exhibit - EX2028 Excerpt of Opening Expert Report of Dr John Bantle Regarding Invalidity of US Patent No 10,335,462, In re Ozempic Semaglutide Patent Litigation, No 22 MD 030
+ More Snippets
Document
IPR2024-00107, No. 2030 Exhibit - EX2030 Excerpt of Opening Expert Report of Dr Paul Dalby Regarding Invalidity of US Patent No 10,335,462, In re Ozempic Semaglutide Patent Litigation, No 22 MD 0303
Cite Document
IPR2024-00107, No. 2030 Exhibit - EX2030 Excerpt of Opening Expert Report of Dr Paul Dalby Regarding Invalidity of US Patent No 10,335,462, In re Ozempic Semaglutide Patent Litigation, No 22 MD 0303
+ More Snippets
Document
IPR2024-00107, No. 1056 Exhibit - US Patent No 5,118,666 (P.T.A.B. Nov. 2, 2023)
Cite Document
IPR2024-00107, No. 1056 Exhibit - US Patent No 5,118,666 (P.T.A.B. Nov. 2, 2023)
+ More Snippets
Document
IPR2024-00107, No. 1016 Exhibit - US Patent Application Pub No US20070010424 (P.T.A.B. Nov. 2, 2023)
Cite Document
IPR2024-00107, No. 1016 Exhibit - US Patent Application Pub No US20070010424 (P.T.A.B. Nov. 2, 2023)
+ More Snippets
Document
IPR2024-00107, No. 1019 Exhibit - Bell, Hamster Preproglucagon Contains the Sequence of Glucagon and Two Rela (P.T.A.B. Nov. 2, 2023)
Cite Document
IPR2024-00107, No. 1019 Exhibit - Bell, Hamster Preproglucagon Contains the Sequence of Glucagon and Two Rela (P.T.A.B. Nov. 2, 2023)
+ More Snippets
Document
IPR2024-00107, No. 1039 Exhibit - Victoza, PHYSICIANS’ DESK REFERENCE 65th ed 2010 (P.T.A.B. Nov. 2, 2023)
Cite Document
IPR2024-00107, No. 1039 Exhibit - Victoza, PHYSICIANS’ DESK REFERENCE 65th ed 2010 (P.T.A.B. Nov. 2, 2023)
+ More Snippets
Document
IPR2024-00107, No. 1093 Exhibit - Declaration of Craig Dyar, PhD (P.T.A.B. Nov. 2, 2023)
Cite Document
IPR2024-00107, No. 1093 Exhibit - Declaration of Craig Dyar, PhD (P.T.A.B. Nov. 2, 2023)
+ More Snippets
Document
IPR2024-00107, No. 1098 Exhibit - Oral Order, Novo Nordisk Inc v Rio Biopharmaceuticals Inc, No 22 294 CFC D Del March 13, 2024 (P.T.A.B. Mar. 15, 2024)
Cite Document
IPR2024-00107, No. 1098 Exhibit - Oral Order, Novo Nordisk Inc v Rio Biopharmaceuticals Inc, No 22 294 CFC D Del March 13, 2024 (P.T.A.B. Mar. 15, 2024)
+ More Snippets
Document
IPR2024-00107, No. 2029 Exhibit - EX2029 Excerpt of Opening Expert Report of William J Jusko, PhD Regarding Invalidity of US Patent No 10,335,462, In re Ozempic Semaglutide Patent Litigation, No 22
Cite Document
IPR2024-00107, No. 2029 Exhibit - EX2029 Excerpt of Opening Expert Report of William J Jusko, PhD Regarding Invalidity of US Patent No 10,335,462, In re Ozempic Semaglutide Patent Litigation, No 22
+ More Snippets
Document
IPR2024-00107, No. 1030 Exhibit - Kim, Effects of Once Weekly Dosing of a Long Acting Release Formulation of (P.T.A.B. Nov. 2, 2023)
Cite Document
IPR2024-00107, No. 1030 Exhibit - Kim, Effects of Once Weekly Dosing of a Long Acting Release Formulation of (P.T.A.B. Nov. 2, 2023)
+ More Snippets